Prof Hoeller speaks with ecancer at EADO 2017 about the timing of combination therapies using PD-1 and CTLA-4 targeted therapies to treat melanoma.
While these targets have been subject to a great deal of investigation independently, Prof Hoeller notes that there is no trial assessing the two in a direct comparison for upfront combination, or one after the other.
He considers the patient subgroups which may benefit most from these differing approaches, based on tumour infiltration and LDH levels, and weighs how toxicity may be managed.
Prof Hoeller also considers how best to assess patient responses to targeted therapies, based on expression of molecular markers including circulating tumour DNA.
